- Home
- FLUX vs INKT Comparison
FLUX vs INKT Comparison
Compare FLUX & INKT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FLUX
- INKT
- Stock Information
- Founded
- FLUX N/A
- INKT 2017
- Country
- FLUX United States
- INKT United States
- Employees
- FLUX N/A
- INKT N/A
- Industry
- FLUX Industrial Machinery/Components
- INKT Medicinal Chemicals and Botanical Products
- Sector
- FLUX Miscellaneous
- INKT Health Care
- Exchange
- FLUX Nasdaq
- INKT Nasdaq
- Market Cap
- FLUX 25.4M
- INKT 28.8M
- IPO Year
- FLUX N/A
- INKT 2021
- Fundamental
- Price
- FLUX $1.90
- INKT $62.86
- Analyst Decision
- FLUX Strong Buy
- INKT Strong Buy
- Analyst Count
- FLUX 2
- INKT 2
- Target Price
- FLUX $6.00
- INKT $37.50
- AVG Volume (30 Days)
- FLUX 132.4K
- INKT 2.3M
- Earning Date
- FLUX 08-15-2025
- INKT 08-12-2025
- Dividend Yield
- FLUX N/A
- INKT N/A
- EPS Growth
- FLUX N/A
- INKT N/A
- EPS
- FLUX N/A
- INKT N/A
- Revenue
- FLUX $63,074,000.00
- INKT N/A
- Revenue This Year
- FLUX $11.10
- INKT N/A
- Revenue Next Year
- FLUX $12.66
- INKT N/A
- P/E Ratio
- FLUX N/A
- INKT N/A
- Revenue Growth
- FLUX N/A
- INKT N/A
- 52 Week Low
- FLUX $1.15
- INKT $4.56
- 52 Week High
- FLUX $4.75
- INKT $74.44
- Technical
- Relative Strength Index (RSI)
- FLUX 58.26
- INKT 57.39
- Support Level
- FLUX $1.36
- INKT $6.80
- Resistance Level
- FLUX $2.53
- INKT $7.88
- Average True Range (ATR)
- FLUX 0.20
- INKT 0.40
- MACD
- FLUX 0.06
- INKT 0.02
- Stochastic Oscillator
- FLUX 52.14
- INKT 58.86
About FLUX Flux Power Holdings Inc.
Flux Power Holdings Inc design, develop, manufacture, and sell a portfolio of lithium-ion energy storage solutions for electrification of a range of industrial commercial sectors which include material handling, airport ground support equipment (GSE), and other commercial and industrial applications. It offers a high-power battery cell management system(BMS). The company's BMS provides three functions to its battery systems which include Cell Balancing, Monitoring, and Error Reporting.
About INKT MiNK Therapeutics Inc.
MiNK Therapeutics Inc is a clinical-stage biopharmaceutical company pioneering the discovery, development, and commercialization of allogeneic invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. The company is advancing a pipeline of both native and next generation engineered iNKT programs, with a platform designed to facilitate scalable and reproducible manufacturing for off-the-shelf delivery.